Alpha 2.0
Login Register
» Authors » Jessica Paulicelli

Jessica Paulicelli

Explore the profile of Jessica Paulicelli including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 43
Followers 0
Related Specialties
Infectious Diseases
Microbiology
General Medicine
Top 10 Co-Authors
Andrea Antinori
Valentina Mazzotta
Enrico Girardi
Alessandra Vergori
Simone Lanini
Francesco Vaia
Roberta Gagliardini
Fabrizio Maggi
Ilaria Mastrorosa
Emanuele Nicastri
Published In
Vaccines (Basel)
J Med Virol
J Clin Med
J Infect
Int J Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous Route
Mazzotta V, Piselli P, Lepri A, Matusali G, Cimini E, Esvan R, et al.
Vaccines (Basel) . 2025 Jan; 13(1). PMID: 39852811
Background: The recent resurgence of mpox in central Africa has been declared a new public health emergency of international concern (PHEIC) requiring coordinated international responses. Vaccination is a priority to...
2.
Effectiveness and Tolerability of DOR/3TC/TDF in Experienced People with HIV Switching from RPV/FTC/TDF: A Retrospective, Single Center Cohort Study
Cicalini S, Lanini S, Gagliardini R, Bellagamba R, Vergori A, Mastrorosa I, et al.
Pharmaceuticals (Basel) . 2025 Jan; 17(12. PMID: 39770548
With advances in antiretroviral therapy for HIV treatment, newer drug combinations provide improved efficacy, safety, and compliance. This study evaluates switching to a regimen of doravirine (DOR), tenofovir disoproxil fumarate...
3.
Impact of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide on psychiatric symptoms and neurocognition
Vergori A, Del Duca G, Lorenzini P, Brita A, Mastrorosa I, Fusto M, et al.
AIDS . 2024 Oct; 39(3):270-275. PMID: 39453875
Objectives: The aim was to investigate whether switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/F/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) may improve neuropsychiatric symptoms and neurocognition. Design: Pilot, single-arm, prospective study of persons...
4.
Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study
Vergori A, Matusali G, Cimini E, Bordi L, Borrelli P, Lanini S, et al.
Vaccines (Basel) . 2024 Jul; 12(7). PMID: 39066422
. We aimed to report the real-world use and outcomes over time in immunocompromised individuals receiving tixagevimab/cilgavimab (T/C) pre-exposure prophylaxis (PrEP). . This observational study included participants who received T/C...
5.
Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era
Vergori A, Lepri A, Chiuchiarelli M, Mazzotta V, Metafuni E, Matusali G, et al.
Int J Infect Dis . 2024 Apr; 144:107042. PMID: 38614231
Objectives: Whether pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab 150 mg/150 mg (T/C) in individuals with hematologic disease (HD) may lead to a reduced risk of SARS-CoV-2 breakthrough infection (BTI)/hospitalization, or death...
6.
Risk Awareness as a Key Determinant of Early Vaccine Uptake in the Mpox Vaccination Campaign in an Italian Region: A Cross-Sectional Analysis
Del Duca G, Tavelli A, Mastrorosa I, Aguglia C, Lanini S, Brita A, et al.
Vaccines (Basel) . 2023 Dec; 11(12). PMID: 38140166
Background: we aim to investigate attitudes toward vaccination by analyzing empirical factors associated with vaccine acceptance in the Lazio region mpox vaccination (MpoxVax) campaign in Italy. Methods: all subjects who...
7.
Rapid ART initiation with bictegravir/emtricitabine/tenofovir alafenamide in individuals presenting with advanced HIV disease (Rainbow study)
Camici M, Gagliardini R, Lanini S, Del Duca G, Mondi A, Ottou S, et al.
Int J Antimicrob Agents . 2023 Dec; 63(1):107049. PMID: 38056572
Background: A rapid ART initiation approach can be beneficial in people with advanced HIV disease, in consideration of their high morbidity and mortality. The aim of our study was to...
8.
Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox
Mazzotta V, Cozzi-Lepri A, Lanini S, Mondi A, Carletti F, Tavelli A, et al.
J Med Virol . 2023 Jun; 95(6):e28868. PMID: 37306318
Tecovirimat is a treatment option for severe mpox, although randomized clinical trials are ongoing. The aim of the study is to assess the effect of tecovirimat on healing time and...
9.
Clinical experience with use of oral Tecovirimat or Intravenous Cidofovir for the treatment of Monkeypox in an Italian reference hospital
Mondi A, Gagliardini R, Mazzotta V, Vita S, Carletti F, Pinnetti C, et al.
J Infect . 2022 Nov; 86(1):66-117. PMID: 36347428
No abstract available.
10.
Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents
Mazzotta V, Lepri A, Colavita F, Rosati S, Lalle E, Cimaglia C, et al.
J Med Virol . 2022 Oct; 95(1):e28186. PMID: 36184918
The efficacy on the Omicron variant of the approved early coronavirus disease-2019 (COVID-19) therapies, especially monoclonal antibodies, has been challenged by in vitro neutralization data, while data on in vivo...